clinical trial · NCT07728019
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology·phase2·not yet recruiting·n = 60
CRC (Colorectal Cancer)SCRTRetlirafusp alfa InjectionBevacizumabCAPOX
brief summary
Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiotherapy in conversion therapy for advanced colorectal cancer liver metastases: an exploratory study.
started
Jul 22, 2026
primary completion
Jun 30, 2029
completion
Dec 31, 2031
last updated
Jul 27, 2026
official title
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With Colorectal Cancer Liver Metastases: a Randomized Phase II Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol